India, Jan. 10 -- Johnson & Johnson (JNJ) announced new longer-term follow-up results from the investigational Phase 1b/2 OrigAMI-1 study evaluating RYBREVANT (amivantamab-vmjw), a bispecific antibody targeting epidermal growth factor receptor (EGFR) and MET. The study assessed RYBREVANT in combination with FOLFOX or FOLFIRI chemotherapy in patients with RAS/BRAF wild-type metastatic colorectal cancer.
Results demonstrated that more than 70 percent of patients in the first-line subgroup responded to treatment with amivantamab plus chemotherapy, with most responses lasting beyond 16 months. These findings highlight the potential of RYBREVANT to deliver durable benefit in a difficult-to-treat patient population.
Notably, encouraging respons...